Sign in

CIK 0001404281

  • Non-accelerated filer
  • Smaller reporting company

Eledon Pharmaceuticals, Inc.

Sign in to watch
Ticker
ELDN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 949-238-8090
Business address
19800 MACARTHUR BLVD., SUITE 250, IRVINE, CA, 92612
Former names
Eledon Pharmaceuticals, Inc., Novus Therapeutics, Inc., Tokai Pharmaceuticals Inc
  1. 4 Open-market sale President sold 9,537 shares at an average $1.95 ($18,612)
  2. 4 Open-market sale See Remarks sold 5,276 shares at an average $1.95 ($10,296)
  3. 4 Open-market sale Chief Executive Officer sold 14,638 shares at an average $1.95 ($28,566)
  4. 4 Open-market buy Director bought 646,204 shares at $3.10 ($2,003,232)
  5. 4 Open-market buy Director bought 646,204 shares at $3.10 ($2,003,232)
  6. 4 Open-market sale 10% owner sold 200 shares at $2.70 ($540)
  7. 4 Grant or award President acquired 20,000 shares (grant or award)
  8. 4 Grant or award Chief Executive Officer acquired 25,000 shares (grant or award)
  9. 4 Derivatives Options or other derivatives
  10. 4 Open-market buy President bought 33,680 shares at an average $4.78 ($161,147)
  11. 4 Open-market buy President bought 805 shares at $3.97 ($3,193)
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 3 Insider Initial Statement of Ownership
  17. 4 Grant or award See Remarks acquired 11,250 shares (grant or award)
  18. 4 Grant or award Chief Executive Officer acquired 30,700 shares (grant or award)
  19. 4 Grant or award President acquired 20,000 shares (grant or award)
  20. 4 Derivatives Options or other derivatives

Page 6 of 11 · 212 filings